Copaxone
(glatiramer acetate)ApprovedSmall molecule
TevaCopaxone is one of 241 small molecule programs targeting Fatigue. It is currently in Approved.
11
Indications
42
Total Trials
1
Active Trials
240
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Copaxone
TevaApproved
Betaseron
BayerPreclinical
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Avonex
EMD SeronoPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Zinbryta
RochePreclinical
Flomax
SanofiPreclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Pletal
OtsukaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis14 trials
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
Unknown status·—·Phase 4·NCT00910598·60 enrolled
Treatment of Multiple Sclerosis With Copaxone and Albuterol
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00039988·40 enrolled
Show 11 more trials
Relapsing-Remitting Multiple Sclerosis6 trials
Safety and Efficacy3 trials
Rett syndrome2 trials
15 more indications
MPR1 trial
Pregnancy1 trial
Disease Progression1 trial
Pediatric Patients1 trial
Optic Neuritis1 trial
Crohn's Disease1 trial
Secondary Progressive Multiple Sclerosis1 trial
Amyotrophic Lateral Sclerosis1 trial
Coagulation1 trial
Outcome1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Dec 20, 1996
COPAXONE
NDA NDA020622
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for glatiramer acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]